| FSC 100/50 | FP 100 | |
|---|---|---|
| Screening | ||
| FEV1 pre-exercise, L | 2.19 ± 0.696 | 2.19 ± 0.711 |
| Maximum fall in FEV1 post-exercise, % | -24.3 ± 10.87 | -24.9 ± 10.27 |
| Post-Run-In (Pre-Randomization) | ||
| FEV1 pre-exercise, | 2.21 ± 0.720 | 2.21 ± 0.711 |
| Maximum fall in FEV1 post-exercise, % | -27.1 ± 7.77 | -28.0 ± 8.59 |
| Morning PEF, L/minute | 268.5 ± 9.14 | 274.2 ± 10.36 |
| Evening PEF, L/minute | 286.6 ± 9.24 | 293.8 ± 10.78 |
| Albuterol-free days, % | 36.5 ± 3.33 | 41.5 ± 3.54 |
| Symptom-free days, % | 15.8 ± 2.24 | 18.0 ± 2.30 |
| Post Treatment (4 weeks) | ||
| FEV1 pre-exercise, L | 2.27 ± 0.073 | 2.24 ± 0.077 |
| Maximum fall in FEV1 post-exercise, % | -9.9 ± 1.01 | -11.1 ± 1.02 (p=0.158) |
| Morning PEF, L/minute | 292.7 ± 9.57 | 290.4 ± 11.10 |
| Change from baseline of morning PEF, L/minute | 23.7 ± 3.95 | 14.2 ± 4.45 (p=0.093) |
| Evening PEF, L/minute | 302.3 ± 9.70 | 297.3 ± 10.91 |
| Change from baseline of evening PEF, L/minute | 14.3 ± 3.44 | 6.2 ± 3.70 (p=0.107) |
| Albuterol-free days, % | 53.4 ± 4.23 | 60.0 ± 3.91 |
| Change from baseline of % albuterol-free days | 16.9 ± 3.23 | 19.1 ± 3.92 (p=0.256) |
| Symptom-free days, % | 27.2 ± 3.89 | 36.2 ± 4.00 |
| Change from baseline of % symptom-free days | 10.9 ± 3.19 | 18.6 ± 4.11 (p=0.056) |